B+
Overall grade
A
Financial quality
The sleeper story is Shield MCD launching in 2025, not waiting for Vanguard results - AmirAli said they're 'not waiting for any other test to be clinical-grade' and will broaden access 'in the near future.' The obvious headline is strong beats across all segments, but the real story is their AI platform driving sustained competitive advantages with G360 Liquid hitting 4th consecutive quarter of acceleration. The binding constraint is now sales execution, not product capability - they're scaling to 250+ reps by year-end to capture demand. Most revealing quote: 'I don't feel rush to get to that [V2] milestone' because of V1's commercial success - they're printing money and can afford to be selective. My view changes if Shield MCD gets delayed beyond Q4 2025 or SERENA-6 monitoring revenue doesn't materialize in 2026.
The 30-second version
- Shield MCD is quietly ready to launch RIGHT NOW - not waiting for Vanguard results
- Tissue ASP hit 2028 target 3 years early at $2,000 - but here's the real story
- Shield V2 data is delayed but they're not rushing because V1 is printing money
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $203.5M (+21% YoY) | $232.1M (+31% YoY) |
| Oncology Revenue | $150.6M (+20% YoY) | $158.7M (+22% YoY) |
| Shield Revenue | $5.7M | $14.8M |
| Shield Gross Margin | Positive (didn't specify %) | 48% |
| Shield ASP | ~$600 | Over $900 |
| Guardant360 Liquid Growth | Accelerated (3rd consecutive quarter) | Over 20% YoY (4th consecutive acceleration) |
| Guardant360 Tissue ASP | $1,700-$1,800 | ~$2,000 |
| Biopharma Revenue | $45.4M (+21% YoY) | $56.0M (+28% YoY) |
Accountability tracked
7 new promises made3 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →